ArticleEuropean journal of nuclear medicine and molecular imaging2026
Refining the clinical utility of [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Beyond [BMC cancer · 2026Pooled it
- Recent advances in PSMA therapy - from beta to alpha.Annals of nuclear medicine · 2026Review
- Progress in the application ofAnnals of nuclear medicine · 2026Review
- Tumor microenvironment-mediated hematologic toxicity ofWorld journal of urology · 2026Review
- Tumor microenvironment-mediated hematologic toxicity ofWorld journal of urology · 2026Review
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics: Design Principles, Structure-Function Relationships, and Preclinical Performance.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the efficacy and safety of Lutetium-177/Actinium-225 prostate-specific membrane antigen tandem radioligand therapy ([
methodsThis retrospective, single-center study included 23 patients with mCRPC who underwent Fluor-18 ([
resultsFollowing two cycles of tandem RLT, 11 patients (48%) achieved a PR. The treatment was generally tolerated well. Grade 3 events included renal impairment in two (9%) and grade 3 anemia in five (22%) patients, while no Grade 4/5 events occurred. Patients with increased PSMA expression on pretherapeutic PET (defined by the average mean standardized uptake value of all tumor lesions [SUV
conclusion[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.